Q2 2026 saw 12% revenue growth, driven by CF and new product launches, with strong global uptake and expanded access. Full-year revenue guidance was raised, and the $10B Crinetics acquisition will add a fifth disease area. Cash reserves remain robust at $13.6B.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.